Navigation Links
Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Date:6/2/2010

Robert Mulroy, President and Chief Executive Officer of Merrimack Pharmaceuticals, will provide a company overview at the Jefferies 2010 Global Life Sciences Conference in New York City.

(PRWEB) June 3, 2010 -- Merrimack Pharmaceuticals today announced that it will present at the Jefferies 2010 Global Life Sciences Conference in New York City. Robert Mulroy, President and Chief Executive Officer, will provide a company overview at 11:00am EST, Wednesday, June 9, 2010 at the Grand Hyatt in New York City, New York.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contacts
Kathleen Petrozzelli, Corporate Communications, 617-441-1043, kpetrozzelli(at)merrimackpharma(dot)com, http://www.merrimackpharma.com
Betsy Raymond Stevenson, RaymondStevenson Healthcare Comms, 860-984-1424, betsy(at)raymondstevenson(dot)com

# # #

Read the full story at http://www.prweb.com/releases/2010/06/prweb4064064.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
5. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
8. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
9. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
10. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
11. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference 
(Date:7/31/2020)... ... July 29, 2020 , ... ... the top radiation centers in 16 countries, has reached its 20th anniversary of ... now in routine use at top universities including University of Pennsylvania, University of ...
(Date:7/18/2020)... (PRWEB) , ... July 16, 2020 , ... After research ... The completion of a great surgery is only the beginning of a successful study, ... research community. , Join Brad Gien, Global Head of Surgery from Envigo ...
(Date:7/18/2020)... ... July 17, 2020 , ... ... for the life sciences and food industries, is pleased to announce that Charles ... Research – Business Development. , Charles is an accomplished and results-driven sales executive ...
(Date:7/10/2020)... ... July 09, 2020 , ... In ... commonly used to suppress pigment formation in zebrafish embryos, maintaining optical transparency to ... by Dr MA has been using the zebrafish model to investigate the causes ...
Breaking Biology Technology:
(Date:6/25/2020)... ... June 24, 2020 , ... ... and software-driven clinical data services that accelerate drug development, is collaborating with Karyopharm ... XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first study ...
(Date:6/23/2020)... England (PRWEB) , ... June 23, 2020 , ... ... Africa supporting sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of ... project to support testing operations in the fight against the COVID-19 pandemic in ...
(Date:6/23/2020)... THE WOODLNDS, Texas (PRWEB) , ... June 23, ... ... in X-ray analytical instrumentation, is pleased to announce the next event in a ... of X-ray scattering. , The TOPIQ series of webinars was developed in response ...
Breaking Biology News(10 mins):